NCT03847974View on ClinicalTrials.gov

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

April 7, 2020

Study Completion Date

August 31, 2020

Conditions
Hypercholesterolemia
Interventions
DRUG

LIB003

300 mg SC Q4W

Trial Locations (3)

45219

Sterling Research Group, Cincinnati

The Lindner Research Center, Cincinnati

45227

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

Sponsors
All Listed Sponsors
lead

LIB Therapeutics LLC

INDUSTRY

NCT03847974 - Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003 | Biotech Hunter | Biotech Hunter